Strategic Focus Shattuck Labs is pursuing first-in-class therapeutics targeting TNF receptor pathways with SL-325 and DR3, indicating a strong opportunity to collaborate on TNF superfamily biology, biomarkers, and endpoint development for IBD and inflammatory diseases.

Clinical-Stage Pathway As a clinical-stage biotech with GLP toxicology data for SL-325 and plans for a Phase 1 healthy volunteer trial, there is potential for co-development, CRO partnerships, or milestone-based collaborations to advance DR3/TL1A pathway programs.

Strategic Partnerships Board additions from industry experts and investors (e.g., OrbiMed connections) alongside notable fundraising activity suggest readiness for strategic alliances, licensing discussions, or co-financing opportunities to accelerate clinically de-risked assets.

Clinical Focus Active engagement in major immunology forums (ECCO, UEG Week) and positive preclinical data publications position Shattuck as a speaker and collaborator for translational research, trial design input, and biomarker strategy discussions.

Operational Footprint Dual offices in Austin and Durham plus a mid-sized team indicate access to biotech hubs for partnering in preclinical to early-phase development, with potential to leverage local CROs, contract manufacturing, and clinical trial networks.